Adenoviral vector-based foot-and-mouth disease vaccine
AssigneeGenVec, Inc.
InventorsDouglas E. Brough, Joseph T. Bruder, C. Richter King, Marvin J. Grubman, John G. Neilan
Life of this patent
Estimating the term…
Abstract
The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.
Claims9
An adenoviral vector comprising an adenoviral genome and at least one nucleic acid sequence encoding an Aphthovirus empty virus capsid and optionally a cytokine operably linked to a promoter, wherein (i) the promoter consists of (a) SEQ ID NO:4, (b) a CMV enhancer/promoter sequence, (c) an untranslated region (UTR), and (d) one or more 3′ splice sequences, and (ii) the adenoviral vector is replication-deficient and requires complementation of only the E1 region, only the E4 region, or only both the E1 and E4 regions of the adenoviral genome for propagation.
Dependencies are inferred from the claim text.